Vaxcyte Tech Stack

Clinical-stage vaccine developer engineering broad-spectrum pneumococcal conjugates

Biotechnology Research San Carlos, California 201–500 employees Founded 2013 Public Company

Vaxcyte is advancing three pneumococcal conjugate vaccine candidates through clinical development, with VAX-31 in Phase 3 adults and Phase 2 infants. The company's technology foundation is XpressCF®, a cell-free protein synthesis platform licensed from Sutro Biopharma that aims to simplify manufacturing of complex vaccines. Active hiring across research (25 roles), engineering (14), and manufacturing (11)—combined with heavy IT projects around SAP S/4HANA implementation, process development, and commercial launch planning—signals a company scaling from clinical validation into manufacturing readiness and regulatory submission.

Tech Stack 26 technologies

Core StackSAP SAP S/4HANA GitHub Copilot Next.js React GraphQL Playwright Cypress GitHub Actions JMP PowerPoint SAP Master Data Management Veeva Veeva Vault HPLC LC-MS SAP SCM SDS-PAGE GC-MS Azure Microsoft Office Ironclad CMMS Veeva QualityDocs

AdoptingSAP SAP S/4HANA LIMS

ReplacingNetSuite

What Vaxcyte Is Building

◆Challenges

Implementing erp system
Launch readiness of critical raw materials
Global regulatory approvals
Compliance with global regulatory guidelines
Erp transformation
Developing robust conjugate vaccine process
Cost containment initiatives
Data consistency and standardization challenges
Master data governance
Transitioning vaccine process to commercial

▲Active Projects

It systems implementation
Pneumococcal conjugate vaccine process development
Sap s/4hana implementation
Technical launch planning
Post-launch process robustness
Enhance the existing legal dashboard using box ai
Adult pneumococcal vaccine vax-31 launch
Polysaccharide conjugate vaccine development
Analytical development and stability studies
Implementation of new software tools

Hiring Activity

Accelerating70 roles · 45 in 30d

Department

Research

Engineering

Manufacturing

Ops

Legal

Product

Quality

Finance

Seniority

Senior

Intern

Mid

Director

Manager

Junior

Notable leadership hires: Regulatory Affairs Director, Medical Affairs Director, Product Launch Lead, Associate Director, Real-World Evidence & Epidemiology, Procurement Director

Company intelligence

Find more companies like Vaxcyte by tech stack, pain points and active projects

Get started free

About Vaxcyte

Vaxcyte engineers pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease. The pipeline centers on VAX-31 (31-valent, broadest-spectrum PCV in clinical testing), VAX-24 (24-valent, designed for infant immunization), and VAX-XL (earlier-stage, using carrier-sparing technology). The company manufactures using XpressCF®, a cell-free protein synthesis platform, which differs from conventional cell-based production. Vaxcyte operates from San Carlos, California, and is publicly traded. Current operational focus spans clinical trial execution, manufacturing process development and robustness, global regulatory pathway coordination, and commercial infrastructure buildout ahead of potential approvals.

HeadquartersSan Carlos, California

Company Size201–500 employees

Founded2013

Hiring MarketsUnited States, Switzerland

Frequently Asked Questions

What is Vaxcyte developing?

Vaxcyte develops pneumococcal conjugate vaccines. Lead candidate VAX-31 covers 31 serotypes and is in Phase 3 trials for adults and Phase 2 for infants. VAX-24, a 24-valent candidate, targets infant immunization. All candidates use XpressCF®, a cell-free protein synthesis platform.

What tech stack does Vaxcyte use?

Core tools include SAP (S/4HANA implementation underway, replacing NetSuite), Veeva Vault and QualityDocs for regulatory/quality, LIMS for lab data, analytical platforms (HPLC, LC-MS, GC-MS), and Microsoft Office. Engineering uses Next.js, React, GraphQL, GitHub Actions, and Playwright/Cypress.